HHS Touts Industry’s Response To Drug Pricing Plan, But Says That’s Not The End Goal

HHS is touting the fact that drug companies took fewer price increases following the launch of the administration's drug pricing plan, but at the same time says progress on controlling prices should not be pegged on industry’s voluntary actions. In a press call with reporters Monday (Aug. 20) HHS both touted its progress and pressed industry and Congress to get behind the president’s blueprint. The administration released a report Monday (Aug. 20) laying out actions the administration took in the...